Maximilian Merz

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

E. K., Uta Bertsch, Jan Dürig et al. · Leukemia · 2015 · 140 citations

Hematological Malignancy, Oncology, Versus Bortezomib +7

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

Maximilian Merz, Thomas Hielscher, Benedikt Wagner et al. · Leukemia · 2014 · 124 citations

Hematological Malignancy, Medical Imaging, Resonance +9

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents

Maximilian Merz, Kai Neben, Marc‐Steffen Raab et al. · Annals of Oncology · 2013 · 76 citations

Hematological Malignancy, Cell Therapy, Transplantation +11

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Maximilian Merz, Hans Salwender, Mathias Haenel et al. · Haematologica · 2015 · 71 citations · Full text

Hematological Malignancy, Oncology, Overall Response Rates +14

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Hartmut Goldschmidt, K. Elias, Jan Dürig et al. · Leukemia · 2020 · 63 citations

Hematological Malignancy, Oncology, Immunology +4